National Defense Industrial Association
Armed Services Biomedical Research Evaluation and Management

20-22 March 2018

RDML Mary Riggs
Director, Defense Health Agency Research Directorate
Chair, ASBREM Col
ASBREM CoI Overview

ASBREM ensures the coordinated delivery of innovative and integrated healthcare solutions to our warfighters: enabling optimal readiness and lethality

- Awareness of cross-Component needs
- Joint alignment of biomedical R&D efforts
- Coordinated & complementary use of resources
- Increased interagency collaborations

2017 Highlights

- Completed Integrated DoD Biomedical Research and Development Strategy
- Developed ASBREM Joint Technology Coordinating Groups (JTCG) Roadmaps aligned to the R&D Strategy
Jointly developed strategy enhances coordination to ensure Warfighters are:

**Goal 1: Better Prepared:** Warfighters are equipped with capabilities and knowledge to optimize their health and achieve peak performance in all mission domains.

**Goal 2: Better Protected:** Warfighters are equipped with capabilities and knowledge to minimize exposure to and consequences of biomedical risks, including infectious diseases, preventable injuries, and other environmental/workplace hazards.

**Goal 3: Better Cared For:** Warfighters are provided with health services that minimize morbidity and mortality and maximize recovery across the treatment continuum; from point of injury, during en route care, to definitive care and rehabilitation.

**Guiding Principles: ASBREM’s commitments**

- Driving innovation in DoD biomedical research
- Maintaining strong biomedical R&D connections to other government agencies, industry, and academia
- Coordinating and integrating portfolios across the DoD
- Improving resource management and efficiency
Biomedical R&D Portfolios
Joint Technology Coordinating Groups

JTCG-1 BIOMEDICAL INFORMATICS & HEALTH INFO SYSTEMS AND TECHNOLOGY (BI/HIST)
Medical Simulation and Training
Health Information Technology and Informatics
Medical Capabilities to Support Dispersed Operations

JTCG-5 MILITARY OPERATIONAL MEDICINE (MOM)
Environmental Health and Protection
Injury Prevention and Reduction
Physiological Health and Performance
Psychological Health and Resilience
Psychiatry and Clinical Psychology Disorders

JTCG-7 MEDICAL RADIOLOGICAL DEFENSE (MRD)
Hematopoietic ARS Recovery Countermeasures
Assessment of Radiation Injury (Biodosimetry)
Combined Injury: Radiation with Other Insults
Internal Contamination
Low Dose/Dose Rate and Late Effects

JTCG-9 MEDICAL CHEM-BIO DEFENSE (MCBD)
Biological Therapeutics
Chemical Therapeutics
Toxin Therapeutics
Biological Prophylaxis
Chemical Prophylaxis
Toxin Prophylaxis
CB Diagnostics

JTCG-2 MILITARY INFECTIOUS DISEASE (MID)
Parasitic Infectious Disease
Bacterial and Fungal Infectious Disease
Viral Infectious Disease
Vector Control
Diagnostics Systems

JTCG-6 COMBAT CASUALTY CARE (CCC)
Prolonged Field Care
Diagnosis and Treatment of Brain Injury
Devices and Therapeutics for Hemorrhage
Control/Resuscitation/Blood Products
En Route Care
Forward Surgical/Intensive Critical Care
Treatments for Extremity Trauma, Tissue Injury, Cranio-maxillofacial Injury, Lung Injury, and Burns
Military Medical Photonics

JTCG-8 CLINICAL AND REHABILITATIVE MEDICINE (CRM)
Neuro-musculoskeletal Injury Rehabilitation
Pain Management (Acute/Chronic/Battlefield)
Regenerative Medicine; Hand and Face Transplants
Sensory Systems (Visual, Auditory, and Vestibular)
ASBREM CoI Accomplishments

Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA): Technique used in trauma for patients that are rapidly bleeding to death from injuries to their chest, abdomen or pelvis

Sufentanil Nano Tab: Rapidly acting product relieves acute pain with minimal side-effects primarily used during Tactical Field Care and Tactical Evacuation Care

Altitude Readiness Management System (ARMS): First mission composite risk management decision aid that monitors probability and severity of high altitude-induced illness or work performance impairment

Zika Vaccine (ZPIV): Rapid 9 month development from bench to clinical trials

Coordinative Accomplishment: Blood Plasma Summit

Brought together DHA J-4, J-9, Army, Navy, SOCOM, DHP, and BARDA stakeholders to coordinate efforts in blood plasma research and development
**Investment Strategy**

**DoD Medical RDT&E Funding Profile 2017 President’s Budget**

*DoD Biomedical R&D investments are primarily targeted in areas, or for environments, that are militarily unique for which there are limited or no commercial partners or interests*

- **The DoD leads** in most biomedical research areas: e.g. prolonged field care, en route care, forward surgical/intensive critical care, hemorrhage control and blood products.

- **The DoD leverages** in areas where commercial technologies exist and can be tailored for military use: e.g. medical simulation and training, diagnostic systems, pain management, infectious diseases, Health Information Technology.

- **The DoD watches** areas of emerging interest: e.g. Medical Radiological Defense and other tech areas like Artificial Intelligence.

**Breakdown by Research Area**

- CCC - Combat Casualty Care: 32%
- MOM - Military Operational Medicine: 24%
- BI/HIST - Bioinformatics and Health IT: 17%
- CRM - Clinical Rehabilitative Medicine: 19%
- MID - Military Infectious Diseases: 17%
- MRD - Medical Radiological Defense: 1%

*BI/HIST- Bioinformatics and Health IT*  
*MID- Military Infectious Diseases*  
*MOM- Military Operational Medicine*  
*CCC- Combat Casualty Care*  
*MRD- Medical Radiological Defense*  
*CRM- Clinical Rehabilitative Medicine*
Conclusion

**Key Areas of Interest**

- Novel tools and techniques for prolonged field care and en route care
- Wearable technology for monitoring environmental and occupational threats
- Technologies to enable autonomous medical supply and evacuation
- Secure and reliable IT and engineering support for telehealth/telecare
- Advancing next generation medical device interoperability and security infrastructure
- Validated models for use as clinical tools to guide therapeutic interventions and predict optimal patient outcomes

*Engaging industry is key to the success of military medical R&D.*

*We look forward to engaging with you.*